249 related articles for article (PubMed ID: 37235767)
1. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
Dogra S; Sharma A; Mehta H; Sarkar R
Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
[TBL] [Abstract][Full Text] [Related]
2. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
4. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
6. [Janus kinase inhibitors : Indications, efficacy, uses, what should be taken into account?].
von Martial S; Tsianakas A
Dermatologie (Heidelb); 2024 Mar; 75(3):256-267. PubMed ID: 38100043
[TBL] [Abstract][Full Text] [Related]
7. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
8. Utilization of Topical Ruxolitinib in Dermatology: A Review.
Kashetsky N; Turchin I
Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
[TBL] [Abstract][Full Text] [Related]
9. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
10. Topical Janus kinase inhibitors: A review of applications in dermatology.
Hosking AM; Juhasz M; Mesinkovska NA
J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
[TBL] [Abstract][Full Text] [Related]
11. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH; Chung WH; Wu PC; Chen CB
Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
[TBL] [Abstract][Full Text] [Related]
12. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
Mancuso-Stewart E; Rodger J; Zirwas M
Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
[TBL] [Abstract][Full Text] [Related]
13. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
Muddebihal A; Khurana A; Sardana K
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology.
Cinats A; Heck E; Robertson L
Skin Therapy Lett; 2018 May; 23(3):5-9. PubMed ID: 29772037
[TBL] [Abstract][Full Text] [Related]
16. Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F; Meier K; Ghoreschi K
Front Immunol; 2019; 10():2847. PubMed ID: 31849996
[TBL] [Abstract][Full Text] [Related]
17. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
20. Emerging trends in clinical research on Janus kinase inhibitors for atopic dermatitis treatment.
Shih PY; Li CJ; Yong SB
Int Immunopharmacol; 2023 Nov; 124(Pt B):111029. PubMed ID: 37820425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
